|
| Press Releases |
|
 |
|
| Tuesday, June 25, 2024 |
|
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
| On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
| On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
| Tuesday, June 18, 2024 |
|
|
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China |
| more info >> |
|
|
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China |
| more info >> |
|
| Tuesday, April 23, 2024 |
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China |
| more info >> |
|
|
China Medical System: New Drug Application of Desidustat Tablets Accepted in China |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets ("Desidustat Tablets" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
| Monday, April 1, 2024 |
|
|
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia |
| more info >> |
|
|
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia |
| more info >> |
|
| Thursday, March 28, 2024 |
|
|
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs |
| more info >> |
|
|
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Honda、「CIVIC」をマイナーモデルチェンジし発売
Sept 12, 2024 11:00: JST
|
|
|
"Ashes of the Kingdom" Breaks Barriers to Captivate the World: Chinese Female-Oriented Games Showcase Global Impact
Sept 11, 2024 23:00 HKT/SGT
|
|
|
Pixotope Forges Strategic Partnership with Happy Elephant Consortium for Asia-Pacific Expansion
Sept 11, 2024 21:00: JST
|
|
|
Pixotope與Happy Elephant Consortium達成戰略合作夥伴關係，推動亞太地區擴展
Sept 11, 2024 20:00 HKT/SGT
|
|
|
Pixotope与Happy Elephant Consortium达成战略合作伙伴关系，推动亚太地区扩展
Sept 11, 2024 20:00 HKT/SGT
|
|
|
Pixotope Forges Strategic Partnership with Happy Elephant Consortium for Asia-Pacific Expansion
Sept 11, 2024 20:00 HKT/SGT
|
|
|
Sculpting Reimagined: Maxon Releases ZBrush for iPad
Sept 11, 2024 20:00 HKT/SGT
|
|
|
Belt and Road Summit Opened Today
Sept 11, 2024 18:22 HKT/SGT
|
|
|
Moody's Reaffirms GTJAI's 'Baa2' Long-term Issuer Rating with a 'Stable' Outlook
Sept 11, 2024 17:28 HKT/SGT
|
|
|
國泰君安國際獲穆迪重申“Baa2” 長期發行人評級，展望“穩定”
Sept 11, 2024 17:12 HKT/SGT
|
|
|
国泰君安国际获穆迪重申“Baa2” 长期发行人评级，展望“稳定”
Sept 11, 2024 17:06 HKT/SGT
|
|
|
Honda Begins Joint Research on AI Technologies with the Indian Institutes of Technology in Delhi and Bombay to Further Advance Honda CI (Cooperative Intelligence)
Sept 11, 2024 16:10 JST
|
|
|
MHI-MS、駐車場などでの自動バレーパーキング、完成車自動搬送向け事業展開を加速
Sept 11, 2024 14:30: JST
|
|
|
Honda、協調人工知能Honda CIのさらなる進化を目指し、インド工科大学デリー校およびボンベイ校とAI技術の共同研究を開始
Sept 11, 2024 14:30: JST
|
|
|
EASD 2024 | 君圣泰医药口头报告熊去氧胆小檗碱（HTD1801）在T2DM中的两项事后分析
Sept 11, 2024 11:51 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
